BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IDP - US09062X1037 - Common Stock
142.75 EUR
-1.6 (-1.11%)
Overall IDP gets a fundamental rating of 6 out of 10. We evaluated IDP against 83 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making IDP a very profitable company, without any liquidiy or solvency issues. IDP is cheap, but on the other hand it scores bad on growth. These ratings could make IDP a good candidate for value investing.
1. Profitability
1.1 Basic Checks
- In the past year IDP was profitable.
- IDP had a positive operating cash flow in the past year.
- In the past 5 years IDP has always been profitable.
- Each year in the past 5 years IDP had a positive operating cash flow.
1.2 Ratios
- IDP has a better Return On Assets (5.51%) than 81.93% of its industry peers.
- Looking at the Return On Equity, with a value of 8.84%, IDP belongs to the top of the industry, outperforming 81.93% of the companies in the same industry.
- IDP has a Return On Invested Capital of 9.70%. This is amongst the best in the industry. IDP outperforms 85.54% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for IDP is below the industry average of 12.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
- Looking at the Profit Margin, with a value of 15.98%, IDP belongs to the top of the industry, outperforming 83.13% of the companies in the same industry.
- IDP's Profit Margin has declined in the last couple of years.
- With an excellent Operating Margin value of 28.50%, IDP belongs to the best of the industry, outperforming 86.75% of the companies in the same industry.
- In the last couple of years the Operating Margin of IDP has declined.
- Looking at the Gross Margin, with a value of 75.24%, IDP is in the better half of the industry, outperforming 66.27% of the companies in the same industry.
- IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
- Compared to 1 year ago, IDP has more shares outstanding
- IDP has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for IDP has been reduced compared to a year ago.
2.2 Solvency
- IDP has an Altman-Z score of 3.23. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of IDP (3.23) is better than 71.08% of its industry peers.
- The Debt to FCF ratio of IDP is 2.78, which is a good value as it means it would take IDP, 2.78 years of fcf income to pay off all of its debts.
- IDP has a better Debt to FCF ratio (2.78) than 83.13% of its industry peers.
- IDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.35, IDP perfoms like the industry average, outperforming 56.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.23 |
ROIC/WACC1.17
WACC8.29%
2.3 Liquidity
- IDP has a Current Ratio of 2.72. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
- IDP has a Current ratio (2.72) which is in line with its industry peers.
- A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
- IDP has a Quick ratio (2.04) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 2.51% over the past year.
- Measured over the past years, IDP shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.31% on average per year.
- The Revenue has been growing slightly by 4.77% in the past year.
- Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -7.62% on average per year.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
- The Earnings Per Share is expected to grow by 0.59% on average over the next years.
- The Revenue is expected to decrease by -0.63% on average over the next years.
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- IDP is valuated reasonably with a Price/Earnings ratio of 9.91.
- Based on the Price/Earnings ratio, IDP is valued cheaply inside the industry as 93.98% of the companies are valued more expensively.
- IDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.47.
- With a Price/Forward Earnings ratio of 10.73, the valuation of IDP can be described as very reasonable.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 97.59% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of IDP to the average of the S&P500 Index (24.26), we can say IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.91 | ||
| Fwd PE | 10.73 |
4.2 Price Multiples
- 92.77% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 96.39% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.76 | ||
| EV/EBITDA | 7.39 |
4.3 Compensation for Growth
- The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
5. Dividend
5.1 Amount
- IDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IDP (1/16/2026, 7:00:00 PM)
142.75
-1.6 (-1.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)01-29 2026-01-29/amc
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap20.94B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.33
Price Target155.43 (8.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)-0.02%
PT rev (3m)4.91%
EPS NQ rev (1m)-1%
EPS NQ rev (3m)-54.86%
EPS NY rev (1m)0.27%
EPS NY rev (3m)-5.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.3%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.91 | ||
| Fwd PE | 10.73 | ||
| P/S | 2.42 | ||
| P/FCF | 10.76 | ||
| P/OCF | 9.92 | ||
| P/B | 1.34 | ||
| P/tB | 10.21 | ||
| EV/EBITDA | 7.39 |
EPS(TTM)14.4
EY10.09%
EPS(NY)13.3
Fwd EY9.32%
FCF(TTM)13.27
FCFY9.29%
OCF(TTM)14.39
OCFY10.08%
SpS59.03
BVpS106.77
TBVpS13.99
PEG (NY)N/A
PEG (5Y)N/A
Graham Number186
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25.04% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.63% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.23 |
F-Score5
WACC8.29%
ROIC/WACC1.17
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-7.54%
EPS Next 2Y-3.12%
EPS Next 3Y-0.66%
EPS Next 5Y0.59%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.95%
Revenue Next 2Y-1.68%
Revenue Next 3Y-1.26%
Revenue Next 5Y-0.63%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year6.14%
EBIT Next 3Y0.99%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
What is the valuation status for IDP stock?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
What is the financial health of BIOGEN INC (IDP.DE) stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.54% in the next year.